Vantictumab - Bayer HealthCare Pharmaceuticals/OncoMed Pharmaceuticals

Drug Profile

Vantictumab - Bayer HealthCare Pharmaceuticals/OncoMed Pharmaceuticals

Alternative Names: Anti-frizzled receptor monoclonal antibody - OncoMed; Anti-Fzd receptor monoclonal antibody - OncoMed; anti-Fzd7; Anti-Fzd7 receptor monoclonal antibody - OncoMed; OMP-18R5; Vantictumab

Latest Information Update: 25 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals; OncoMed Pharmaceuticals
  • Developer OncoMed Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Frizzled-receptor-antagonists; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer; Non-small cell lung cancer; Pancreatic cancer

Highest Development Phases

  • Suspended Breast cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 18 Apr 2018 Pharmacodynamics data from a preclinical study in Cancer presented at the Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 01 Jun 2017 OncoMed Pharmaceuticals completes a phase I trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease, Recurrent) in USA (NCT01957007)
  • 08 May 2017 OncoMed Pharmaceuticals suspends patient enrolment in a phase I trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease, Recurrent) in USA following a recent bone adverse event that occurred in a patient receiving vantictumab plus paclitaxel in a phase Ib HER2-negative breast cancer trial (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top